A study to evaluate the effect of ezetimibe and rosuvastatin on intravascular ultrasound-derived coronary atheroma and lipid lowering effect.
- Conditions
- dyslipidemia
- Registration Number
- JPRN-UMIN000010323
- Lead Sponsor
- Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
- Brief Summary
Intensive lipid-lowering therapy with ezetimibe provide greater reduction in the percent change in plaque volume (PV), the primary endpoint, than the statin monotherapy group (-13.2% versus -3.1%, respectively, P = 0.050).Moreover, percent change in PV showed positive correlations with percent change of LDL-C (r = 0.384, P = 0.015). Intensive lipid-lowering therapy with ezetimibe added to usual-dose statin may provide significant incremental reduction in coronary plaques compared with usual-dose statin monotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1, privious allergy for ezetimibe or any of statins 2, contraindication for rosuvastatin and already recieved rosuvastatin 3, secondary dyslipidemia 4, history of acute coronary syndrome within 3months before study entry 5, congestive heart failure (NYHA 3 or 4) 6, low left ventricular contractility 7, inducation for coronary artery bypass graft 8, poor control HTN patient (systolic BP over 220mmHg, diastolic BP over 110mmHg) 9, poor control diabetic patient (HbA1c over 9.5%) 10, hemodialysis patient 11, severe renal dysfunction (30 over CCr or serum Cre over 2.0) 12, serum CK over 300 13, severe liver dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method